VarmX raises €32m in Series B financing round | Allergy Therapeutics (AGY.L): Invalidation of 2019 Phase 3 trial primary endpoint testing PQ-Birch
09 Jul 2020
SP Angel Healthcare Conditions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
SP Angel Healthcare Conditions
Allergy Therapeutics plc (AGY:LON) | 3.0 0 0.0% | Mkt Cap: 143.0m
- Published:
09 Jul 2020 -
Author:
Vadim Alexandre | Liam Gascoigne-Cohen -
Pages:
3
VarmX raises €32m in Series B financing round | Allergy Therapeutics (AGY.L): Invalidation of 2019 Phase 3 trial primary endpoint testing PQ-Birch